Overview

Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. The rates of clinically significant DVT will be equivalent between two groups.
Phase:
N/A
Details
Lead Sponsor:
University of Tennessee
Treatments:
Calcium heparin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin